Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05026489
Other study ID # XJTU1AF2021LSK-285
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 1, 2021
Est. completion date December 31, 2023

Study information

Verified date August 2021
Source First Affiliated Hospital Xi'an Jiaotong University
Contact Hongmei Cao, Professor
Phone 008618991232710
Email chm1027@163.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Cerebral infarction brings heavy burden to patients and families with high morbidity, mortality, disability and recurrence rate. Anti-platelet aggregation therapy plays important role for secondary prevention of cerebral infarction. G6PD deficiency is a rare genetic disorder, patients with this disorder could suffer hemolysis after eating broad beans. Professor Zeng Jinsheng et al found that the hemolysis risk of G6PD deficiency patients was significantly increased when aspirin was applied in Guangdong Province. However, the prevalence of G6PD deficiency in northern China remains unknown, as well as the safety of antiplatelet therapy. To this end, 1000 patients with acute cerebral infarction will be continuously included in 30 second-level and above hospitals in 10 prefectures and cities of Shaanxi Province for observation and follow-up for 12 months, to explore the prevalence of G6PD deficiency in cerebral infarction patients in Shaanxi Province, and to analyze the relationship between G6PD deficiency and the clinical characteristics and prognosis of cerebral infarction. To clarify the efficacy and safety of antiplatelet therapy for G6PD patients with cerebral infarction is of great significance for guiding the individualized treatment of cerebral infarction.


Recruitment information / eligibility

Status Recruiting
Enrollment 1000
Est. completion date December 31, 2023
Est. primary completion date December 31, 2022
Accepts healthy volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - meets the diagnostic criteria of acute cerebral infarction established by Neurology Society of Chinese Medical Association, and confirmed by cranial Magnetic Resonance Imaging; - Time from onset to enrollment =14 days; - Volunteer to participate in the study and sign the informed consent. Exclusion Criteria: - Silent cerebral infarction with no symptoms and signs; - Complicated with post-infarction hemorrhage; - Cerebral hernia and other complications caused by massive cerebral infarction may lead to death in acute phase; - Cardiogenic cerebral embolism caused by atrial fibrillation; - Cerebral infarction caused by tumor, vasculitis and other special reasons; - Complicated with serious systemic diseases, including liver and kidney insufficiency, respiratory failure, heart failure, infection, etc

Study Design


Related Conditions & MeSH terms


Intervention

Genetic:
G6PD gene deficiency
we will use tetrazolazole-blue quantitative method to detect whether the patient suffer from G6PD deficiency.

Locations

Country Name City State
China Xi'an Jiatong University Xi'an Shaanxi

Sponsors (2)

Lead Sponsor Collaborator
First Affiliated Hospital Xi'an Jiaotong University Simcere Company

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Prevalence of G6PD deficiency Prevalence of G6PD deficiency in cerebral infarction patients in Shaanxi Province up to 24 weeks
Secondary National Institute of Health stroke scale on a scale of 0-42, the higher the score, the more damage of the nervous system 1 year
Secondary All-cause mortality rate All-cause mortality was calculated in % for both groups 1 year
See also
  Status Clinical Trial Phase
Withdrawn NCT02551003 - Neuroprotective Effect of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonatal Encephalopathy Phase 1/Phase 2
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Recruiting NCT03605381 - MORbidity PRevalence Estimate In StrokE
Completed NCT00684515 - Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017) Phase 2
Not yet recruiting NCT04082091 - Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention
Completed NCT01915368 - Determining Optimal Post-Stroke Exercise (DOSE) N/A
Terminated NCT01684462 - The Efficacy and Safety Study of ALbumin Therapy in Acute Ischemic Stroke Phase 2
Completed NCT00386191 - Safety and Efficacy of Clopidogrel for Cerebral Infarction Treatment Phase 4
Completed NCT00004734 - Vitamin Therapy for Prevention of Stroke Phase 3
Completed NCT02684825 - Detection of Silent Atrial Fibrillation aFter Ischemic StrOke N/A
Completed NCT02248233 - Nimodipine for Treating Acute Massive Cerebral Infarction Phase 4
Completed NCT02963545 - TSK (Tryptophan - Serotonin - Kynurenine) Biomarkers Assessment in Stroke N/A
Completed NCT02511249 - Early Determinants of Multidimensional Outcome at School Age After Neonatal Arterial Ischemic Stroke N/A
Completed NCT02101606 - Penumbral Based Novel Thrombolytic Therapy in Acute Ischemic Stroke Phase 2
Completed NCT00829361 - Stroke Telemedicine for Arizona Rural Residents Trial N/A
Completed NCT01500421 - Safty and Feasibility Study of Therapeutic Cooling in Acute Ischemic Stroke (COOLAID Øresund) Phase 2
Recruiting NCT01003470 - Treating Apoplectic Sequela With Acupuncture: a Randomized Controlled Study Phase 2
Terminated NCT00331890 - ICTUS Study: International Citicoline Trial on Acute Stroke Phase 3
Not yet recruiting NCT04696523 - Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage Phase 2
Completed NCT03741400 - Virtual Reality Glove for Hand and Arm Rehabilitation After Stroke N/A